A Study of Engineered Donor Grafts (TregGraft/Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT04013685
Trial Phases:	Phase I	Protocol IDs:	TRGFT-201 (primary) NCI-2019-08529
Eligibility:	18 - 65 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Orca Biosystems, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04013685

Summary

This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft
("TregGraft"/"Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T
Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic
hematopoietic cell transplant transplantation for hematologic malignancies.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.